- •Women at risk for hereditary gynecologic cancers have unique concerns regarding fertility and hormonal health.
- •There are multiple fertility preservation strategies that can be used to help women achieve their procreative goals.
- •Genetic testing can be used before embryo transfer to identify whether an embryo carries a pathogenic gene variant.
- •For women with who don’t have a personal history of breast cancer, hormone therapy can be considered.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Obstet. Gynecol. 2017; 130: e110-e126
- Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.Am. J. Hum. Genet. 2003; 72: 1117-1130
- Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.Clin. Cancer Res. 2002; 8: 3776-3781
- Lynch Syndrome. Obstet Gynecol. 2014; 124: 1042-1054
- Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.JAMA. 2011; 305: 2304-2310
- Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study.J Cin Oncol. 2017; 35: 1411-1420
- Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis.Obstet. Gynecol. 2013; 122: 139-147
- Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.Eur. J. Cancer. 2010; 46: 2275-2284
- Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review.Cancer Epidemiol. Biomark. Prev. 2013; 22: 1931-1943
- Contemporary hormonal contraception and the risk of breast Cancer.N. Engl. J. Med. 2018; 378: 1265-1266
- Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer.Cancer. 2015; 121 (Jul 1): 2108-2120
- Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.JAMA. 2010; 304: 967-975
- Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.Lancet Oncol. 2006; 7: 223-229
- Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.J. Clin. Oncol. 2014; 32 (May 20): 1547-1553
- Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.J. Clin. Oncol. 2005; 23: 127-132
- Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.J. Clin. Oncol. 2007; 25: 3985-3990
Birrer N, Chinchilla C, Del Carmen M, Dizon DS. Is Hormone replacement therapy safe in women with a BRCA mutation? A systematic review of the contemporary literature. Am. J. Clin. Oncol. 2016 (Feb 2. [Epub ahead of print).
- BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.Gynecol. Oncol. 2004; 92: 521-524
. Shu CA1, Pike MC2, Jotwani AR3, Friebel TM4, Soslow RA5, Levine DA6, Nathanson KL7, Konner JA8, Arnold AG3, Bogomolniy F6, Dao F6,. Uterine cancer after risk-reducing Salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016 Nov 1; 2(11): 1434–1440. doi:https://doi.org/10.1001/jamaoncol.2016.1820.
- Incidence of endometrial cancer in relation to the use of oral contraceptives.N. Engl. J. Med. 1980; 302: 551-554
- Prospective, multi-center randomized intermediate biomarker study of Oral contraceptive vs. Depo-Provera for prevention of endometrial cancer in women with Lynch syndrome.Cancer Prev. Res. (Phila.). 2013 Aug; 6 (Published online 2013 May 2) (PMCID: PMC3737517): 774-781
- Levonorgestrel-releasing intrauterine system use is associated with decrease risk of ovarian and endometrial cancer without increased risk of breast cancer. Results from the NOWAC study.Gynecol. Oncol. 2018; 149: 127-132
- Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the Levonorgetrel-releasing intrauterine device.Obstet. Gynecol. 2018; 131: 109-116
- Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.N. Engl. J. Med. 2006; 354: 261-269
- A pilot study of BRCA mutation carriers’ knowledge about the clinical impact of prophylactic oophorectomy and views on fertility consultation: a single–center pilot study.J Genet Counsel. 2015; 24: 149-157
Chan JL, Johnson LNC, Sammel MD, DiGiovanni L, Voong C, Domchek SM, et al. Reproductive decision–making in women with BRCA1/2 mutations. J Genet Counsel. (ePub ahead of print).
- Association between biomarkers of ovarian reserve an infertility among older women of reproductive age.JAMA. 2017; 318: 1367-1376
- Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California.Cancer. 2013; 119: 1652-1659
- Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.J. Clin. Oncol. 2013; 31: 3920-3925
- Premature menopause in patients with BRCA1 gene mutation.Breast Cancer Res. Treat. 2006; 100: 59-63
- Ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian Cancer risks.JCO. 2010; 28: 240-244
- BRCA1 germline mutations may be associated with reduced ovarian reserve.Fertil. Steril. 2014; 102: 1723-1728
- Association of BRCA1 mutations with impaired ovarian reserve: connection between infertility and breast/ovarian Cancer risk.J Adolescent and Young Adult Oncology. 2016; 5: 337-343
- BRCA mutation carriers do not have compromised ovarian reserve.Int. J. Gynecol. Cancer. 2014; 24: 233-237
- BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.Fertil. Steril. 2015; 104: 1162-1167
- Impact of BRCA mutations on female fertility and offspring sex ratio.Am. J. Hum. Biol. 2010; 22: 201-205
- Fertility in women with BRCA mutations: a case-control study.Fertil. Steril. 2010; 93: 1805-1808
- BRCA mutations increase fertility in families at hereditary breast/ovarian cancer risk.PLoS One. 2015; 10e0127363
- Anti-Mullerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.Hum. Reprod. 2016; 31: 1126-1132
- Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline.Fertil. Steril. 2013 Jan; 99 (Epub 2012 Oct 22.): 37-43https://doi.org/10.1016/j.fertnstert.2013.09.028
- Fertility drugs and cancer: a guideline.Fertil. Steril. 2016; 106: 1617-1625
- Long-term safety of Letrozole and gonadotropin stimulation for fertility preservation in women with breast Cancer.Clin. Endocrinol. Metab. 2016; 101: 1364-1371
- Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.Fertil. Steril. 2015; 103 (May): 1305-1312
- Hereditary Breast Cancer Clinical Study Group. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.Fertil. Steril. 2016; 105 (Mar): 781-785
- First live birth after uterus transplantation in the United States.Am. J. Transplant. 2018; 18: 1270-1274
Practice Committee of Society for Assisted Reproductive Technology; Practice Committee of American Society for Reproductive Medicine. Preimplantation genetic testing: a practice committee opinion. Fertil. Steril. 2008; 90: S136–43.
- Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors.Breast Cancer Res. Treat. 2014; 145: 673-681
- BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis.Genet Med. 2012; 14 (May): 527-534
- Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.Familial Cancer. 2008; 7: 179-186
- Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer.Hum. Reprod. 2007; 22 (Jun): 1573-1577
- The evolving role of genetics in reproductive medicine.Obstet. Gynecol. Clin. N. Am. 2014; 41: 41-55
- Practice bulletin no. 163 summary: screening for fetal aneuploidy.Obstet. Gynecol. 2016 May; 127 (MID: 27101120): 979-981https://doi.org/10.1097/AOG.0000000000001439
- Hormone therapy in oophorectomized BRCA1/2 mutation carriers.Menopause. 2014; 21: 763-768
- Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.Gynecol. Oncol. 2011; 122: 339-343
- The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.Gynecol. Oncol. 2011; 121: 163-168
- BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.Womens Health (Lond). 2012; 8: 543-555
- Collaborative group on hormonal factors in breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer.Lancet. 1997; 1997: 1047-1059
- Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study.Obstet. Gynecol. 2009; 113: 1027-1037
- Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women’s Health Initiative observational study.Arch. Intern. Med. 2011; 171: 760-768
∗This article is published jointly in Gynecologic Oncology and Fertility & Sterility